2F5
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, focuses on developing, manufacturing, and commercializing inflammation and immunology biological products for the treatment of infectious and autoimmune diseases in Israel. It develops nanosized VHH antibodies (nanoAbs) targeting diseases with unmet medical needs; and PC111, a monoclonal antibody for treating pemphigus, steven johnson's… Read more
2F5 (2F5) - Net Assets
Latest net assets as of June 2025: €7.86 Million EUR
Based on the latest financial reports, 2F5 (2F5) has net assets worth €7.86 Million EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€11.84 Million) and total liabilities (€3.98 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €7.86 Million |
| % of Total Assets | 66.37% |
| Annual Growth Rate | 116.55% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
2F5 - Net Assets Trend (2021–2024)
This chart illustrates how 2F5's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for 2F5 (2021–2024)
The table below shows the annual net assets of 2F5 from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €9.98 Million | +318.36% |
| 2023-12-31 | €-4.57 Million | -159.60% |
| 2022-12-31 | €-1.76 Million | -279.23% |
| 2021-12-31 | €982.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to 2F5's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 750000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €127.52 Million | 1278.10% |
| Total Equity | €9.98 Million | 100.00% |
2F5 Competitors by Market Cap
The table below lists competitors of 2F5 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hacisco JSC
VN:HAS
|
$2.14 Million |
|
RENFORTH RESS. INC. NEW
F:9RR
|
$2.14 Million |
|
Manydev Studio SE
WAR:MAN
|
$2.14 Million |
|
Evolving Systems Inc
PINK:EVOL
|
$2.14 Million |
|
Star Vault AB (publ)
PINK:SRVTF
|
$2.14 Million |
|
TVD Holdings PCL
BK:TVDH
|
$2.13 Million |
|
Aruma Resources Ltd
AU:AAJ
|
$2.13 Million |
|
Acticor Biotech SAS
PA:ALACT
|
$2.13 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in 2F5's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -4,569,000 to 9,977,000, a change of 14,546,000.
- Net income of 4,796,000 contributed positively to equity growth.
- New share issuances of 2,000,000 increased equity.
- Other factors increased equity by 7,750,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €4.80 Million | +48.07% |
| Share Issuances | €2.00 Million | +20.05% |
| Other Changes | €7.75 Million | +77.68% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares 2F5's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 201.77x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 444.03x to 201.77x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €0.00 | €0.59 | x |
| 2022-12-31 | €0.00 | €0.59 | x |
| 2023-12-31 | €0.00 | €0.59 | x |
| 2024-12-31 | €0.00 | €0.59 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently 2F5 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 48.07%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 728.88%
- • Asset Turnover: 0.05x
- • Equity Multiplier: 1.35x
- Recent ROE (48.07%) is above the historical average (-196.89%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -835.64% | 0.00% | 0.00x | 32.62x | €-8.30 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | €-5.62 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | €-6.04 Million |
| 2024 | 48.07% | 728.88% | 0.05x | 1.35x | €3.80 Million |
Industry Comparison
This section compares 2F5's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,495,893,796
- Average return on equity (ROE) among peers: -668.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| 2F5 (2F5) | €7.86 Million | -835.64% | 0.51x | $2.14 Million |
| 09R (09R) | $5.86 Million | -145.33% | 0.68x | $12.96 Million |
| IDORSIA AG (19T) | $104.20 Million | -608.99% | 13.23x | $582.75 Million |
| 1S90 (1S90) | $10.78 Million | -2319.92% | 31.35x | $54.21 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.28 Million |
| 25K0 (25K0) | $-79.67 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $508.00K | -2193.11% | 12.24x | $9.80 Million |
| Intervacc AB (publ) (2E9) | $308.25 Million | -9.53% | 0.07x | $3.46 Million |
| 2H0 (2H0) | $3.03 Million | -558.03% | 2.82x | $9.20 Million |
| GNI Group Ltd (3G6) | $13.10 Billion | 1.39% | 0.57x | $772.60 Million |